1307801-59-7

Basic information

• Product Name: (1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methanol
• Synonyms: (1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methanol
• CAS NO: 1307801-59-7
• Molecular Weight: 327.361
• Mol File: 1307801-59-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methanol(1307801-59-7)
• EPA Substance Registry System: (1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methanol(1307801-59-7)

Safety Data

• Hazardous Substances Data: 1307801-59-7(Hazardous Substances Data)

Upstream product

• 1307803-02-6 ethyl 1-(2-chloro-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carboxylate 
• 85290-78-4 ethyl 3-methylpyrazole-4-carboxylate 
• 1307803-03-7 (1-(2-chloro-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-yl)methanol 
• 108-69-0 3,5-dimethylaminoaniline 

Downstream Products

• 1307803-06-0 1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde 
• 1307801-93-9 2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methylamino)ethanol 
• 1351503-99-5 C₃₀H₄₂N₆O₅ 
• 1307802-53-4 2,2-dimethyl-1-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-1H-pyrrol-3-yl)methyl)-1,4-diazepan-1-yl)propan-1-one 

Relevant articles and documents

KINASE INHIBITORS

The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.